Aberrant chromatin regulation as a molecular mechanism of MLL--ENL leukemogenesis
Authors:
S. Takáčová 1; M. Jarošová 2; V. Divoký 1
Authors‘ workplace:
Ústav biologie LF UP Olomouc
1; Hemato-onkologická klinika FN Olomouc
2
Published in:
Transfuze Hematol. dnes,13, 2007, No. 1, p. 16-22.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Chromosomal aberrations that affect the Mixed-Lineage Leukemia gene (MLL, known also as HRX or ALL-1) located at 11q23 are associated with an aggressive type of acute leukemia. Frequent translocations create a diverse set of MLL fusion genes with acquired active transforming potential resulting in leukemic conversion of MLL transcription factor. The normal MLL protein is involved in epigenetic maintenance of homeotic (Hox) gene expression through several rounds of cell division during development and differentiation. Alterations of this process by oncogenic MLL chimeric transcription factors lead to leukemia. This review is intended to provide a coherent view on normal and malignant function of MLL proteins - mainly focusing on MLL-ENL - in our current knowledge. Our own contribution to the field is also summarized in this review.
Key words:
acute leukemia, MLL, translocation, chromatin, epigenetics, transcription
Sources
1. Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax to the AF-4 gene. Cell 1992; 71: 701-708.
2. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukemias. Nat Genet 1992; 2: 113–118.
3. Tkachuk DC, Kohler S, Cleary M. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691–700.
4. Gu Y, Alder H, Nakamura T, Schichman SA, Prasad R, Canaani O, Saito H, Croce CM, Canaani E. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res 1994; 54: 2326–2330.
5. Strout M, Marcucci G, Bloomfield CD., Caligiuri MA. The partial tandem duplication of ALL-1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA 95, 2390–2395 (1998).
6. Strissel P, Strick R, Rowley JD, Zeleznik-Le NJ. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region. Blood 1998; 92: 3793–3803.
7. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001; 20: 5695–5707.
8. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematom Educ Program) 2004; 80–97.
9. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003; 102: 262–268.
10. Hess J. MLL: a histon methyltransferase disrupted in leukemia. Trends in Mol Med 2004; 10: 500–507.
11. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226–4237.
12. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122–129.
13. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol Cell Biol 2002; 22: 6542–6552.
14. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA 2000; 97: 10984–10989.
15. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 2000; 19: 4655–4664.
16. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. Blood 2002; 99: 3780–3785.
17. Corral J, Lavenir I, Impey H, Warren AJ, et al. An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996; 85: 853–861.
18. Dobson CL, Warren AJ, Pannell R, Forster A, et al. The MLL-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukemogenesis. EMBO J 1999; 18: 3564–3574.
19. Forster A, Pannell R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 2003; 3: 449–458.
20. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995; 378: 505–508.
21. Jarosova M, Takacova S, Holzerova M, et al. Cryptic MLL-AF10 fusion caused by insertion of duplicated 5’ part of MLL into 10p12 in acute leukemia: a case report. Cancer Genet Cytogenet 2005; 162: 179–182.
22. Kohlmann A, Schoch C, Dugas M, Schnittger S, Hiddemann W, Kern W, Haferlach T. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 2005; 19: 953–964.
23. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003; 102: 262-268.
24. Erfurth F, Hemenway CS, de Erkenez AC, Domer PH. MLL fusion partners AF4 and AF9 interact at subnuclear foci. Leukemia 2004; 18: 92–102.
25. Zeisig DT, Bittner CB, Zeisig BB, Garcia-Cuellar MP, Hess JL, Slany RK. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 2005; 24: 5525–5532.
26. Slany RK. When epigenetics kills: MLL fusion proteins in leukemia. Hematol Oncol 2005; 23: 1–9.
27. Jamieson CH, Weissman IL and Passeque E. Chronic versus acute myelogenous leukemia: A question of self-renewal. Cancer Cell 2004; 6: 531–533.
28. Cozzio A, Passegue E, Anton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029–3035.
29. Zeisig BB, Milne TA, Garcia-Cuellar MP, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004; 24: 617–628.
30. Horton SJ, Grier DG, McGonigle GJ, Thompson A, Morrow M, De Silva I, Moulding DA, Kioussis D, Lappin TRJ, Brady HJM, Williams O. Continuous MLL-ENL expression is necessary to establish a “Hox code” and maintain immortalization of hematopoietic progenitor cells. Cancer Res 2005; 65: 9245–9252.
31. Schreiner S, Birke M, Garcia-Cuellar MP, Zilles O, Greil J, Slany RK. MLL-ENL Causes a Reversible and myc-dependent Block of Myelomonocytic Cell Differentiation. Cancer Res 2001; 61: 6480–6486.
32. Hanson RD, Hess JL, Yu BD, Ernst P, van Lohuizen M, Berns A, van der Lugt NMT, Shashikant CS, Ruddle FH, Seto M, Korsmeyer SJ. Mammalian Trithorax and Polycomb-group homologues are antagonistic regulators of homeotic development. Proc Natl Acad Sci USA 1999; 96: 14372–14377.
33. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 1998; 95: 10632–10636.
34. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107–1117.
35. Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002; 10: 1119–1128.
36. Dou Y, Milne AT, Tackett AJ, et al. Physical Association and Coordinate Function of the H3 K4 Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF. Cell 2005; 121: 873–885.
37. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci USA 2005; 102: 14765–14770.
38. Guenther MG, Jenner RG, Chevalier B, et al. Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci USA 2005; 102: 8603–8608.
39. Slany RK. Chromatin control of gene expression: Mixed-lineage leukemia methyltransferase SETs the stage for transcription. Proc Natl Acad Sci USA 2005; 102: 14481–14482.
40. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hoxa9 locus, promoting transcription and multiple histone modifications. Cancer Res 2005; 65: 11367–11374.
41. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–870.
42. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem 2005; 26: 24315–24321.
43. Pui Ch, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 15: 1535–1548.
44. Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 2003; 115: 293–303.
45. Yokohama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 2002; 100: 3710–3718.
46. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol 2003; 23: 186–194.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2007 Issue 1
Most read in this issue
- Results and complications of splenectomy in patients with severe thrombocytopenia in ITP resistant to initial conservative therapy – centre experience
- A relationship of serum imunoglobulin free light chain levels measurement to multiple myeloma staging
- From the monitoring of Bcr/Abl fusion gene level in patient with chronic myeloid leukemia to the imatinib resistance detection – case report
- Therapy of follicular lymphoma - latest developments